ARV-102 vs BIIB122 / DNL151 (LRRK2 inhibitor)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: LRRK2 · full Parkinson's Disease pipeline
ARV-102
Developed by Arvinas Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
BIIB122 / DNL151 (LRRK2 inhibitor)
Developed by Biogen under a licence from Denali Therapeutics
NCT05418673 · Phase 3 · terminated
Although the trial was designed as a randomized, blinded, placebo-controlled study, it enrolled only 7 participants and was stopped early by the sponsor before anyone completed it. Because of this, no data are reported for the primary measure of disease progression, so the trial does not provide usable evidence on whether the drug works.
Next expected readout: March 2027 · NCT06602193 (registry estimate)
Reported efficacy
Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score Over the Treatment Period (Up to Week 144): Phase 2b LUMA (n=648, randomized, placebo-controlled) did not slow confirmed clinical worsening; Biogen and Denali said in May 2026 that they would discontinue BIIB122/DNL151 development in idiopathic Parkinson's disease. Denali continues the Phase 2a BEACON study in LRRK2-variant carriers. (missed)
Result source: NCT05348785
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ARV-102 | BIIB122 / DNL151 (LRRK2 inhibitor) |
|---|---|---|
| OFF time, change | —Not reported | —Not reported |
| ON time without troublesome dyskinesia, change | —Not reported | —Not reported |
| UPDRS Part III, change | —Not reported | —Not reported |
| MDS-UPDRS Part II, change | —Not reported | —Not reported |
OFF time, change
- ARV-102
- —Not reported
- BIIB122 / DNL151 (LRRK2 inhibitor)
- —Not reported
ON time without troublesome dyskinesia, change
- ARV-102
- —Not reported
- BIIB122 / DNL151 (LRRK2 inhibitor)
- —Not reported
UPDRS Part III, change
- ARV-102
- —Not reported
- BIIB122 / DNL151 (LRRK2 inhibitor)
- —Not reported
MDS-UPDRS Part II, change
- ARV-102
- —Not reported
- BIIB122 / DNL151 (LRRK2 inhibitor)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ARV-102: no structured comparison results are available for Parkinson's Disease.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ARV-102: 0 of 4 rows · BIIB122 / DNL151 (LRRK2 inhibitor): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | BIIB122 / DNL151 (LRRK2 inhibitor) |
|---|---|
| Dropout rate | n/a: no completion milestone225 mga NCT05418673 · Phase 3 · monotherapy |
| Discontinued due to AEs | —225 mga NCT05418673 · Phase 3 · monotherapy |
| Serious AEs | —225 mga NCT05418673 · Phase 3 · monotherapy |
| Most frequent reported AEs | — |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ARV-102's landscape · BIIB122 / DNL151 (LRRK2 inhibitor)'s landscape